ArticleCureus2026
Autoimmune Encephalitis Associated With Anti-Contactin-Associated Protein-Like 2 (Anti-CASPR2) Antibodies in an Elderly Patient: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The leading cause of epilepsy in the elderly is cerebrovascular disease. Autoimmune encephalitis (AE) is an increasingly recognized cause of new-onset seizures in older adults, particularly when no structural lesion or infectious aetiology is identified and when there are unexplained new-onset seizures, particularly in focal status epilepticus. We report the case of a 77-year-old male with anti-contactin-associated protein-like 2 (anti-CASPR2) encephalitis whose initial brain MRI and routine labs were unremarkable. Despite the negative imaging and routine blood tests, clinical evaluation yielded a high Antibody Prevalence in Epilepsy and Encephalopathy (APE2) and the Response to Immunotherapy in Epilepsy 2 (RITE2) scores (8 points), justifying the early initiation of methylprednisolone and intravenous immunoglobulin. Following intensive management and antibody confirmation in serum and cerebrospinal fluid tests, the patient achieved significant clinical improvement, seizure control, and successful tapering of antiseizure medications. This case emphasizes that AE is an important and potentially treatable cause of new-onset epilepsy in the elderly. Early recognition using validated clinical scales such as APE2 and RITE2 can support prompt immunotherapy and improve outcomes beyond antiseizure treatment alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.